Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIXC NASDAQ:DYAI NASDAQ:RNAZ NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIXCQualigen Therapeutics$1.38-8.1%$1.30$0.92▼$8.81$27.43M0.5263,430 shs21,470 shsDYAIDyadic International$0.75+3.3%$0.82$0.65▼$1.35$27.26M1.1864,812 shs10,690 shsRNAZTransCode Therapeutics$6.83-2.5%$8.83$6.08▼$20.99$6.28M1.39174,044 shs1,461 shsTPSTTempest Therapeutics$1.91-1.5%$1.97$1.50▼$12.23$27.39M-1.75175,606 shs11,790 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIXCQualigen Therapeutics+9.49%+1.35%+10.29%+9.49%+149,999,900.00%DYAIDyadic International-5.52%-8.33%-18.70%-13.05%-32.32%RNAZTransCode Therapeutics-4.37%-10.60%-14.74%-33.46%-24.65%TPSTTempest Therapeutics-2.51%-4.90%-5.37%-19.83%-70.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIXCQualigen Therapeutics$1.38-8.1%$1.30$0.92▼$8.81$27.43M0.5263,430 shs21,470 shsDYAIDyadic International$0.75+3.3%$0.82$0.65▼$1.35$27.26M1.1864,812 shs10,690 shsRNAZTransCode Therapeutics$6.83-2.5%$8.83$6.08▼$20.99$6.28M1.39174,044 shs1,461 shsTPSTTempest Therapeutics$1.91-1.5%$1.97$1.50▼$12.23$27.39M-1.75175,606 shs11,790 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIXCQualigen Therapeutics+9.49%+1.35%+10.29%+9.49%+149,999,900.00%DYAIDyadic International-5.52%-8.33%-18.70%-13.05%-32.32%RNAZTransCode Therapeutics-4.37%-10.60%-14.74%-33.46%-24.65%TPSTTempest Therapeutics-2.51%-4.90%-5.37%-19.83%-70.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIXCQualigen Therapeutics 1.00SellN/AN/ADYAIDyadic International 2.33Hold$3.00301.07% UpsideRNAZTransCode Therapeutics 1.00SellN/AN/ATPSTTempest Therapeutics 2.50Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest RNAZ, TPST, AIXC, and DYAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026AIXCQualigen Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026RNAZTransCode Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/2/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/27/2026DYAIDyadic International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIXCQualigen TherapeuticsN/AN/AN/AN/A($0.75) per shareN/ADYAIDyadic International$3.09M8.82N/AN/A$0.03 per share24.93RNAZTransCode TherapeuticsN/AN/AN/AN/A$11.27 per shareN/ATPSTTempest TherapeuticsN/AN/AN/AN/A$1.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIXCQualigen Therapeutics-$16.97M-$7.50N/AN/AN/AN/AN/A-83.21%N/ADYAIDyadic International-$7.36M-$0.25N/AN/AN/A-239.67%-695.96%-78.24%5/13/2026 (Estimated)RNAZTransCode Therapeutics-$34.66M-$99.36N/AN/AN/AN/A-382.87%-57.10%N/ATPSTTempest Therapeutics-$26.26M-$6.64N/AN/AN/AN/A-309.60%-115.81%5/12/2026 (Estimated)Latest RNAZ, TPST, AIXC, and DYAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026DYAIDyadic International-$0.04N/AN/AN/A$0.90 millionN/A5/12/2026Q1 2026AIXCQualigen TherapeuticsN/A-$0.79N/A-$0.79N/AN/A5/12/2026Q1 2026TPSTTempest Therapeutics-$0.28N/AN/AN/AN/AN/A3/30/2026Q4 2025AIXCQualigen TherapeuticsN/A-$3.76N/A-$3.76N/AN/A3/30/2026Q4 2025TPSTTempest Therapeutics-$0.62-$0.62N/A-$0.62N/AN/A3/25/2026Q4 2025DYAIDyadic International-$0.03-$0.06-$0.03-$0.06$1.34 million$0.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIXCQualigen TherapeuticsN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIXCQualigen TherapeuticsN/A9.309.30DYAIDyadic International4.082.682.68RNAZTransCode TherapeuticsN/A6.296.29TPSTTempest TherapeuticsN/A2.502.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIXCQualigen Therapeutics3.18%DYAIDyadic International27.95%RNAZTransCode TherapeuticsN/ATPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipAIXCQualigen Therapeutics1.17%DYAIDyadic International29.50%RNAZTransCode Therapeutics0.01%TPSTTempest Therapeutics6.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIXCQualigen Therapeutics5020.24 million20.00 millionN/ADYAIDyadic International736.44 million25.69 millionOptionableRNAZTransCode Therapeutics9920,000917,000Not OptionableTPSTTempest Therapeutics2014.34 million13.44 millionNo DataRNAZ, TPST, AIXC, and DYAI HeadlinesRecent News About These CompaniesTempest Therapeutics (TPST) Expected to Announce Earnings on TuesdayMay 10 at 4:07 AM | americanbankingnews.comTempest Presents Clinical Update at ISCT 2026 Annual MeetingMay 6, 2026 | globenewswire.comTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingApril 29, 2026 | globenewswire.comTempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-TApril 22, 2026 | globenewswire.comTempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing EffortsApril 14, 2026 | globenewswire.comNew Strong Buy Stocks for April 10thApril 10, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST)April 1, 2026 | theglobeandmail.comTempest Reports Year End 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comTempest Therapeutics (NASDAQ:TPST) CEO Matthew Angel Acquires 231,482 SharesMarch 26, 2026 | insidertrades.comTempest Therapeutics Announces Up To $6 Million Private PlacementMarch 23, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 12, 2026 | finanznachrichten.deTempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 11, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026February 26, 2026 | finanznachrichten.deTempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026February 25, 2026 | globenewswire.comTempest Therapeutics to Prioritize Development of Newly Acquired CAR T-Cell ProgramsFebruary 11, 2026 | precisionmedicineonline.comPTempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T AssetsFebruary 11, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T AssetsFebruary 5, 2026 | finanznachrichten.deTempest Therapeutics Closes All-Stock Transaction to Acquire Next-Generation CAR-T Assets and Appoints Matt Angel as CEOFebruary 4, 2026 | quiverquant.comQTempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T AssetsFebruary 4, 2026 | globenewswire.comTempest Therapeutics (TPST) price target increased by 22.22% to 11.22February 4, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNAZ, TPST, AIXC, and DYAI Company DescriptionsQualigen Therapeutics NASDAQ:AIXC$1.38 -0.12 (-8.07%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Dyadic International NASDAQ:DYAI$0.75 +0.02 (+3.29%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.TransCode Therapeutics NASDAQ:RNAZ$6.82 -0.18 (-2.50%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.Tempest Therapeutics NASDAQ:TPST$1.91 -0.03 (-1.55%) As of 11:02 AM Eastern This is a fair market value price provided by Massive. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
